IPCA Laboratories share news, announcements and annual reports
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
IPCA Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Feb 1995 on NSE
Last close ₹1,927.80up ₹1.60 (0.08%)BSE ₹1,927.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,926.20.
30 Oct: open ₹1,945.20, high ₹1,964.90, low ₹1,921.40
52-week range of traded prices to 30 Oct 2026
₹1,268.00Low, 31 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹48,909 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,53,52767.6% delivered
IPCA Laboratories share news and announcements
772 announcements, routine notices left out, newest first. Page 5 of 16.
Sep 2022
30 Sep · Disclosure of other UPSI/material event
30 Sep · Rating
27 Sep · Rating
19 Sep · Analysts
Aug 2022
11 Aug · Meeting
5 Aug · Analysts
Jul 2022
14 Jul · Meeting
7 Jul · General updates
May 2022
24 May · Results
20 May · Analysts
Apr 2022
Feb 2022
14 Feb · Board meeting
14 Feb · Results
10 Feb · Analysts
9 Feb · Analysts
Jan 2022
31 Jan · Board meeting
Dec 2021
24 Dec · Corporate action
14 Dec · Analysts
Nov 2021
24 Nov · Board meeting
17 Nov · Analysts
13 Nov · Corporate action
13 Nov · Results
10 Nov · Analysts
Oct 2021
29 Oct · Rating
20 Oct · Corporate action
1 Oct · Business
Sep 2021
27 Sep · Analysts
13 Sep · Analysts
7 Sep · Rating